Prosecution Insights
Last updated: October 26, 2026
Application No. 18/941,686

METHOD OF TREATING TEETH USING AN ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES

Non-Final OA §DP
Filed
Nov 08, 2024
Priority
Oct 19, 2020 — provisional 63/093,518 +6 more
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Procter & Gamble Company
OA Round
1 (Non-Final)
46%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
465 granted / 1005 resolved
-13.7% vs TC avg
Strong +19% interview lift
Without
With
+18.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
54 currently pending
Career history
1064
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
52.1%
+12.1% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
16.3%
-23.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1005 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Nonstatutory Obvious-type Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). 1) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,201,705. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 2) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-21 of U.S. Patent No. 11,833,231. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 3) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 11,826,437. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 4) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of U.S. Patent No. 11,839,666. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 5) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-26 of U.S. Patent No. 11,904,033. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 6) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 11,839,667. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 7) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,208,149. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 8) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,133,903. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. 9) Claims 1-20 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 12,133,904. Although the claims at issue are not identical, they are not patentably distinct from each other because they both claim an oral care article comprising a water insoluble delivery carrier, solid hydrophilic particles comprising a bleaching agent, wherein the particles are dispersed in and embedded in the solid water insoluble delivery carrier. Conclusion Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Nov 08, 2024
Application Filed
Aug 25, 2026
Non-Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758476
ACID RESISTANT COMPOSITION HAVING IMPROVED SOLUBILITY
4y 4m to grant Granted Oct 13, 2026
Patent 12758483
ANTIBACTERIAL AND MINERALIZING COMPOSITIONS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12746108
Two Phase System to Administer a Dose of an Active to Animals
2y 11m to grant Granted Sep 29, 2026
Patent 12734118
Oral Care Compositions
5y 7m to grant Granted Sep 15, 2026
Patent 12728080
COSMETIC KIT WITH A CLEANSING STICK, DISPENSING CONTAINER, AND CUTTING DEVICE
2y 2m to grant Granted Sep 08, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
46%
Grant Probability
65%
With Interview (+18.8%)
3y 4m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1005 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month